Clinical P pharmaphorum
Clinical trial setup times fall sharply in UK
Clinical trial setup times fall sharply in UK Phil.Taylor Thu, 22/10/2026 - 10:01
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Clinical P pharmaphorum
Clinical trial setup times fall sharply in UK Phil.Taylor Thu, 22/10/2026 - 10:01
Clinical A Applied Clinical Trials
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Industry
Pharmaceutical Technology
Fenwick partners Chelsea Anderson and Noah Solowiejczyk outline how prediction markets will impact how biotechs operate.
Clinical
Clinical Trials Arena
HealthBio has initiated a multi-centre clinical trial, HBT-002, to assess its lead compound Inflamexa in adult patients with PTLDS. The post HealthBio begins multi-centre trial of Inflamexa for PTLDS appeared first on Clinical Trials Arena.
Software
Pharmaceutical Technology
AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.
Industry S Science News
X-ray experiments reveal cubic crystals that could complicate the picture of the inner core
Industry B BioTechniques
Original story from Texas A&M University (TX, USA). Scientists unlock a groundbreaking discovery about the origins of life with absorption, fluorescence and Raman spectroscopy. Scientists have long sought to understand the complex origins of intelligent life. Emerging during…
Clinical P pharmaphorum
UK trial 'could halve time to test Alzheimer's drugs' Phil.Taylor Thu, 22/10/2026 - 08:57
Industry
European Biotechnology
Swedish private equity firm EQT wants to acquire diagnostics specialist Qiagen for €10.8 billion, or €46.50 per share. The company’s leadership unanimously supports the sale. Completion is planned for mid-2027 if more than 50% of shareholders agree. The post Qiagen agrees to go p…
Industry
Clinical Trials Arena
Tracy Vanderslice, VP of Clinical Operations at Gilead Sciences, who also works with TransCelerate, explains the current challenges of PI oversight and the solutions. The post Podcast: Do PI signatures really signal meaningful oversight? appeared first on Clinical Trials Arena.
Industry B BioTechniques
Naoki Harikai (right) is a Professor in the Division of Analytical Chemistry, School of Pharmacy at Nihon University (Tokyo, Japan), whose research is rooted in pharmaceutical analytical chemistry, primarily developing simple, highly sensitive assays for nucleic acid detection an…
Regulatory
Clinical Trials Arena
The FDA has authorised Lynch Regenerative Medicine’s IND application for a Phase II study of injectable rhPDGF-BB to treat adults with IOH. The post Lynch’s rhPDGF-BB IND secures FDA clearance for Phase II trial appeared first on Clinical Trials Arena.
Regulatory
Pharmaceutical Technology
The EC has approved MSD Keytruda plus Padcev as perioperative treatment for resectable muscle-invasive bladder cancer (MIBC) in adults.
Software W Weekly Bioinformatics
A distilled model passed every automatic check and still got more of the biology wrong. A 23-row table of verified facts did what fine-tuning and retrieval could not.
Industry P Pharmafile
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the acute treatment of migraine with or without aura in adults meeting specified criteria. The recommendation applies where at least two triptans – medicines prescribed for migraine…
Clinical
European Biotechnology
An experimental oral drug for early Alzheimer's disease has produced positive Phase 1 results, including shifts in spinal-fluid markers of brain immune activity and neuronal stress in older volunteers toward levels seen in younger people, Danish biotech Muna Therapeutics reported…
Funding
European Biotechnology
Icelandic biotech Arctic Therapeutics has raised $21.5 million (€19.1 million) in an oversubscribed round to take two drug candidates for autoimmune disease toward the clinic. The post Arctic Therapeutics raises $21.5M to take autoimmune programs to clinic appeared first on Europ…
Industry S Science News
Researchers estimate climate change is responsible for two-thirds of the deaths
Industry P pharmaphorum
12 Questions with Julia Jakl Nicole.Raleigh Thu, 22/10/2026 - 07:00
Manufacturing
European Biotechnology
At the IZB in Martinsried, Invitris is developing a cell-free platform to turn digital sequences into proteins, antibodies and phages within hours. CEO Patrick Grossmann explains why AI is shifting the bottleneck from drug design to manufacturing, how Phactory™ addresses phage p…
Software M MetaphysicalCells
If you would like a deeper dive, subscribe to MetaphysicalCells and visit the free archive of the TechBio News weekly newsletter 📚, about Science, Technology and AI Drug Discovery.This Substack is reader-supported.
Industry
BioSpace
The $100,000 H-1B visa fee has significantly affected who biopharma companies hire, according to two experts. It’s not the only program adjustment affecting foreign-born job seekers’ odds of working in the U.S.
Agriculture S Science News
Scientists stress need for further study of Shamonda virus but say there’s no cause for alarm
Industry S Science News
Tam Dao, who investigated foreign attempts to obtain U.S.-funded research, now has a grant to determine the extent of the threat
Industry I In the Pipeline
I’m always glad to see articles like this one, where someone goes to the trouble of confirming whether “Compound X is a selective probe for Protein Target Y” is a true statement. That’s because it’s not all that easy to find a selective probe! A basic rule of small molecules in b…
Industry
BioCentury
BIOCENTURY | EMERGING COMPANY PROFILEAPTADIR: SWITCHING SILENCED GENES BACK ON WITH TARGETED DEMETHYLATIONMilan-based biotech raised a €40M seed round to take RNA-DNA chimeras into the clinic, starting with fragile X syndrome
Industry
BioCentury
BIOCENTURY | MANAGEMENT TRACKSCSL, VOYAGER INTRODUCE INCOMING CEOSAustralian biopharma taps ViiV’s Waterhouse; Swartz to succeed Sandrock at gene therapy company
Industry N Nature Reviews Bioengineering
Research N Nature Medicine
Industry
Nature Biotechnology
Industry
Nature Biotechnology
Software J JEFworks
Introduction
Industry N Nature Medicine
Funding
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTCHINA’S IIT OVERHAUL HAS NARROWED ACCESS AND RAISED STANDARDSInvestigators report a sharp drop in study approvals under Order 818 but see benefits for patient safety and data quality
Software A Arcadia Science
We present a reusable, cloud-scalable pipeline that pairs Cellpose-SAM segmentation with on-demand GPU compute for single-cell phenotyping of high-content microscopy, demonstrated on a two-species yeast panel (_S. cerevisiae_ versus _S. pombe_).
Manufacturing B BioProcess International
A leader from San Jacinto College talks about how working with NIBRT is helping to prepare Houston for today’s biomanufacturing jobs.
Industry B BioPharm International
Sanofi breaks ground on an EU-backed insulin API plant in Frankfurt, Summit and ECOG-ACRIN launch a phase 2/3 trial of ivonescimab in first-line biliary tract cancer, and TaiMed’s anti-CD4 antibody TMB-365 lowers HIV viral load in phase 1.
Clinical
C&EN Pharmaceuticals
F2G and Shionogi’s olorofim met its goals in a late-stage study, setting the stage for an FDA filing this year
Industry
MedTech Dive
Dr. Michelle Tarver said the FDA’s device center is filling positions after losing large numbers of clinical reviewers and AI and digital health experts.
Industry
MedTech Dive
Facing continued softness, Intuitive outlined opportunities to increase use of its robots in benign general surgeries.